# TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

> **NCT07266298** · PHASE1 · RECRUITING · sponsor: **Neowise Biotechnology** · enrollment: 24 (estimated)

## Conditions studied

- Solid Metastatic Tumor

## Interventions

- **BIOLOGICAL:** NW-101C

## Key facts

- **NCT ID:** NCT07266298
- **Lead sponsor:** Neowise Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2028-12
- **Final completion:** 2030-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266298, "TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07266298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*